ANDERNACH, Germany, Oct. 13, 2025 /PRNewswire/ — LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC (“Renaissance”), a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms.

With the acquisition, Renaissance facilities will become part of the worldwide operations network of LTS, along with LTS’ existing facilities in Andernach, Germany, West Caldwell, NJ, US, St. Paul, MN, US and Netanya, Israel.

The acquisition of Renaissance marks a significant milestone in LTS’s strategy to expand its capabilities in the CDMO space. Renaissance brings deep expertise, state-of-the-art manufacturing infrastructure, and a talented workforce of approximately 500 employees. This move enables LTS to offer a broader range of drug delivery solutions and strengthens its position within the CDMO community.

Founded in 1979 and currently owned by RoundTable Healthcare Partners, Renaissance is headquartered in Lakewood, New Jersey. The company operates multiple manufacturing suites for unit-dose, bi-dose, multi-dose nasal sprays, and small-volume parenteral fill-finish vials. Its laboratories support R&D formulation development and spray characterization, making Renaissance a comprehensive partner from development through commercial launch.

This acquisition aligns with LTS’s commitment to innovation and excellence in drug delivery. By integrating Renaissance’s capabilities, LTS will be better positioned to serve pharmaceutical and biotech partners across a wider spectrum of therapeutic modalities.

Bas van Buijtenen, CEO of LTS, commented: “We are delighted to welcome Renaissance Lakewood to the LTS family. This acquisition marks a significant step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions. Renaissance’s expertise in nasal sprays and sterile dosage forms perfectly complements our existing portfolio and will enable us to offer even greater value to our partners and patients worldwide. We look forward to working together to drive innovation and deliver high-quality solutions across a broader range of therapeutic modalities.”

Serge Maltais, President & CEO of Renaissance added: “I am incredibly proud of what we have built at Renaissance thanks to the hard work and dedication of our employees. Now, as part of the LTS family, our combined strengths will position us even better to meet the complex needs of our clients and deliver greater value to the industry. We are excited to begin this new chapter and look forward to achieving success together.”

The transaction is expected to close before end of November 2025, subject to regulatory approvals.

About LTS Lohmann Therapie-Systeme AG

We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China. Learn more about LTS www.ltslohmann.com.

About Renaissance Lakewood, LLC (“Renaissance”)

Renaissance is a US-based contract development and manufacturing organization (CDMO) for pharmaceutical and biotech. With over 20 years of experience in nasal sprays and sterile dosage forms, Renaissance has a consistent track record of providing exceptional service and resources to clients from the development stage through commercial launch. Learn more about Renaissance at: www.renpharm.com

For further information, please contact:

LTS Lohmann Therapie-Systeme AG
Dr Iris Schnitzler: iris.schnitzler@ltslohmann.com; +49 2632 992589

Renaissance Media Contact
media@renpharm.com
732-730-3262

BRISBANE, Calif. , Oct. 13, 2025 /PRNewswire/ — ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational therapy for Charcot-Marie-Tooth disease (CMT). ReviR is preparing to launch a Phase 1 clinical trial in healthy volunteers in early 2026 to evaluate the safety, tolerability, and pharmacokinetics of RTX-117, with a Phase Ib/IIa study in CMT patients planned to follow. 

CMT is the most prevalent inherited peripheral neuropathy, affecting an estimated 125,000 to 150,000 individuals in the United States and more than 2.6 million patients worldwide. It is a progressive, debilitating genetic disorder for which there are currently no approved treatment options, representing a significant unmet medical need.

RTX-117 is designed to activate eIF2B to restore translation of cap-dependent mRNAs to normalize protein expression, aiming to address an underlying cause of Charcot-Marie-Tooth disease rather than just alleviating symptoms. This differentiated approach has the potential to slow or halt disease progression and improve neuromuscular function. 

The FDA’s Orphan Drug Designation program is a program designed to encourage the development for drugs and biologics that are intended for the treatment, prevention, or diagnosis of rare diseases or conditions affecting fewer than 200,000 people in the U.S. Benefits of the designation include tax credits for clinical research, exemption from certain FDA fees, and the potential for seven years of market exclusivity upon FDA approval.

“Charcot-Marie-Tooth disease represents one of the most prevalent inherited peripheral neuropathies in the world, yet effective disease-modifying therapies remain elusive,” said Paul August, PhD, Chief Scientific Officer of ReviR Therapeutics, and a leading expert in neurodegenerative disease therapeutics. “The progressive nature of CMT is characterized by distal muscle weakness, sensory loss, and significant mobility impairment creating an urgent need for therapeutic intervention. Receiving Orphan Drug Designation for RTX-117 represents a pivotal milestone in addressing this critical unmet medical need. Our preclinical work has demonstrated RTX-117’s potential to target the dysregulated pathophysiology of CMT. This FDA designation not only validates the scientific rationale behind our approach at ReviR, but also provides crucial regulatory support that will accelerate our clinical development timeline. We remain steadfast in our commitment to translating years of rigorous research into a therapeutic solution for the CMT patient community.”

“We believe RTX-117 and our broader pipeline have the potential to deliver disease-modifying therapies to patients with serious conditions who currently have limited or no treatment options,” added Peng Yue, Chief Executive Officer of ReviR Therapeutics.

About ReviR Therapeutics

ReviR Therapeutics is a global biotechnology company committed to discovering and developing innovative therapies for patients with serious neurogenetic diseases worldwide. ReviR was founded in 2021 by leaders in computational biology, RNA biology, and drug discovery, with the aim to create disease-modifying therapies that are highly specific, efficacious, and safe. ReviR’s lead candidate, RTX-117, is an investigational small molecule therapy for Charcot-Marie-Tooth disease (CMT). In addition, ReviR’s pipeline includes other orally administered small molecules designed to modulate RNA function. For more information about ReviR Therapeutics, visit www.revirtx.com or contact info@revirtx.com.

TAIPEI, Oct. 13, 2025 /PRNewswire/ — Mrs. Nancy Hsu, Managing Director of Far Eastern Department Stores Ltd. (FEDS), has been honored with the Master Entrepreneur award at the Asia Pacific Enterprise Awards (APEA) 2025 Taiwan Chapter, recognizing her exceptional leadership and lasting contributions to Taiwan’s retail landscape. At the same time, FEDS achieved two prestigious accolades—the Inspirational Brand award and Corporate Excellence award—representing a landmark moment that highlights both Nancy Hsu’s visionary leadership and the company’s outstanding performance.

With over four decades of experience in the retail industry, Mrs. Nancy Hsu has become one of Taiwan’s most respected business leaders, renowned for her ability to turn crises into opportunities. Guided by her philosophy, “Retail is detail,” she has led FEDS through pivotal transformations, including the successful opening of five next-generation department stores.

During the COVID-19 pandemic, when many competitors faced severe challenges, Nancy Hsu’s decisive leadership enabled FEDS to achieve growth against the odds. Her influence extends beyond her company; as Chairperson of the Retailers Association of Chinese Taipei, she negotiated key tax incentives and secured resources to support the broader retail sector. In November 2024, she spearheaded a historic delegation to Japan, marking the first-ever exchange between the department store associations from Taiwan Region and Japan, paving the way for future collaboration in the region.

This legacy of innovation and resilience is reflected in the company’s achievements. As Taiwan’s longest-operating department store chain, FEDS has continuously evolved over its 58-year history through five generations of transformation, redefining the retail experience for modern consumers. By diversifying into department stores, shopping malls, hypermarkets, and premium supermarkets, FEDS has built a multi-faceted retail ecosystem that addresses a wide range of customer needs. Embracing digital transformation, the company integrates AI and advanced technologies to deliver seamless omnichannel shopping experiences that connect online and offline services.

FEDS is also a trailblazer in sustainability. Since 2011, all newly opened stores have incorporated eco-friendly building principles such as energy conservation, waste reduction, and environmental health, reflecting the company’s deep commitment to environmental responsibility. These efforts extend across operations through initiatives focused on energy saving, carbon reduction, renewable energy, and green procurement. The company also actively engages in social welfare projects and supports local agriculture, guided by the belief of “giving back to society what is taken from society.”

This triple recognition at the APEA 2025 Taiwan is a testament to Nancy Hsu’s visionary leadership and the collective dedication of the FEDS team. Together, they have not only elevated the company’s standing in the retail market, but also set a benchmark for innovation, sustainability, and social responsibility.

About Enterprise Asia
Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine toward sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplifting the economic status of people across Asia and ensuring a legacy of hope, innovation, and courage for future generations. Please visit https://www.enterpriseasia.org/ for more information.

About Asia Pacific Enterprise Awards
Launched in 2007, the Asia Pacific Enterprise Awards is the region’s most prestigious award for outstanding entrepreneurship, continuous innovation, and sustainable leadership. The Award provides a platform for companies and governments to recognize entrepreneurial excellence, hence spurring greater innovation, fair business practices, and growth in entrepreneurship. As a regional award, it groups together leading entrepreneurs as a powerful voice for entrepreneurship and serves as a by-invitation-only networking powerhouse. The program has grown to encompass 16 countries/ regions and markets all over Asia. For further information, please visit www.apea.asia.